NCT05457257 - Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

October 22, 2024

Study Completion Date

September 30, 2025

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

olaparib

300 mg (2x 150 mg tablets) twice daily

DRUG

enzalutamide

160 mg (4 x 40 mg capsules) once daily

DRUG

abiraterone acetate

1,000 mg (4 x 250 mg tablets) once daily

DRUG

Prednisone

5mg(5mg x 1 tablet) twice daily

Trial Locations (35)

100050

Research Site, Beijing

110004

Research Site, Shenyang

200002

Research Site, Shanghai

200032

Research Site, Shanghai

214002

Research Site, Wuxi

214023

Research Site, Wuxi

215004

Research Site, Suzhou

226361

Research Site, Nantong

230601

Research Site, Hefei

233004

Research Site, Bengbu

250012

Research Site, Jinan

250021

Research Site, Jinan

272029

Research Site, Jining

276000

Research Site, Linyi

300060

Research Site, Tianjin

310003

Research Site, Hangzhou

310009

Research Site, Hangzhou

310014

Research Site, Hangzhou

314001

Research Site, Jiaxing

315010

Research Site, Ningbo

330006

Research Site, Nanchang

350005

Research Site, Fuzhou

404000

Research Site, Wanzhou

408099

Research Site, Chongqing

410008

Research Site, Changsha

410013

Research Site, Changsha

430022

Research Site, Wuhan

450052

Research Site, Zhengzhou

510060

Research Site, Guangzhou

510180

Research Site, Guangzhou

610000

Research Site, Chengdu

650101

Research Site, Kunming

710077

Research Site, Xi'an

730030

Research Site, Lanzhou

030000

Research Site, Taiyuan